Skip to content
Buy This GLP
← Research
Evidence

Does Compounded Semaglutide Work? 4.6% Lost in 3 Months in One Cohort

A 94-person cohort observed 4.57% average weight loss at three months with compounded semaglutide and B12. Other records studies also reported weight loss, but they cannot establish equivalence to Wegovy.

Editorial profile: Carla MedinaBuy This GLP Editorial Team5 min read
Mean weight loss at different follow-up timesCompounded, with B123 months4.57%Mayo clinic cohort3 months5.9%Mayo follow-up subset6 months10.9%STEP 1 trial68 weeks14.9%Separate studies and time points. No matched comparison.

What studies of compounded injections found

A 2025 study reviewed records of 94 people receiving weekly compounded semaglutide with cyanocobalamin, a form of vitamin B12, in a commercial wellness program. Mean weight loss at three months was 4.11 kg, or 4.57% of starting body weight. The study had no control group, so it could not isolate the effects of the medication, B12, or the program. All authors reported salary support from Restore Hyper Wellness [1].

When interpreting claims about adding B12 to semaglutide, keep in mind that every participant received the combination, so the study could not isolate a B12 effect. Absolute lean mass and skeletal muscle mass fell, even though their shares of total weight increased [1].

A separate retrospective study from the Australian Juniper program compared compounded and noncompounded semaglutide with health coaching. Among participants with eligible follow-up weights, mean loss around four months was 9.11% in the compounded group (923 people) and 9.87% in the noncompounded group (1,858). Patients were not randomly assigned. The analysis used available follow-up and was not a trial against Wegovy. Two authors reported salaries from Juniper’s parent company [4].

A 2026 preprint analyzed a matched sample of 3,657 existing Noom users across three programs. At 16 weeks, estimated average weight loss was 8.3% and 9.1% in the two groups prescribed compounded semaglutide and 2.6% in the behavioral program group. Patients chose their programs. The study used observational data, all authors reported working for Noom as employees or contractors, and the preprint had not undergone peer review as of this update [5].

How to read the Wegovy and Mayo results

The Mayo Clinic cohort recorded mean losses of 5.9% at three months among 175 patients and 10.9% at six months among 102. Those figures combine patients who received different semaglutide doses. Only 77 of the 175 reached 1.7 or 2.4 mg[2]. The three- and six-month averages therefore describe groups with different follow-up counts.

The randomized STEP 1 trial enrolled 1,961 adults with overweight or obesity and no diabetes. With lifestyle intervention in both groups, mean weight loss at 68 weeks was 14.9% with weekly semaglutide targeted to 2.4 mg and 2.4% with placebo [3]. The guide to weight loss reported in GLP-1 studies explains why dose, follow-up and patient population matter when comparing these averages.

What FDA policy means for these findings

The FDA does not preapprove compounded semaglutide for safety, quality or effectiveness [6]. The post-shortage compounding rules depend in part on whether a state-licensed pharmacy or an outsourcing facility makes the product. Under section 503A, an exception to FDA’s copy analysis can depend on a prescriber documenting that the compounded change makes a significant difference for a specific patient. FDA says adding B12 can still result in a product it considers essentially a copy. Under section 503B, separate restrictions apply to compounding from bulk substances. FDA’s April 2026 guidance said semaglutide was on neither the 503B bulk substances list nor the drug shortage list[7].

These studies examined injections. If you are reading claims about under-the-tongue semaglutide, the route and formulation need their own evidence. Outcomes from an injection cannot establish how much of an under-the-tongue formulation reaches the bloodstream or what weight loss it produces.

Frequently asked

Is compounded semaglutide effective?
Observational studies have reported weight loss among people using some compounded semaglutide injections. In one study, 94 people using injections with vitamin B12 lost an average of 4.57% at three months. The study had no control group.
Does compounded semaglutide work as well as Wegovy?
The evidence described here does not establish that. The Australian records study compared compounded and noncompounded semaglutide within one service. It did not randomly assign treatment or directly compare the preparation with Wegovy.
Does the evidence apply to sublingual semaglutide?
The weight-loss studies described here used injections. Sublingual drops and dissolving tablets need their own evidence for absorption and weight loss.

Sources

  1. [1] Chun E, et al. (2025). Weight loss and body composition after compounded semaglutide treatment in a real world setting Diabetes, Obesity and Metabolism. PMID 39776038
  2. [2] Ghusn W, et al. (2022). Weight Loss Outcomes Associated With Semaglutide Treatment for Patients With Overweight or Obesity JAMA Network Open. PMID 36121652
  3. [3] Wilding JPH, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity New England Journal of Medicine. PMID 33567185
  4. [4] Talay L, et al. (2024). Effectiveness and Side Effect Incidence in a Real-World Digital Weight-Loss Service Using Compounded Semaglutide: A Retrospective Comparative Study Obesities. Source
  5. [5] Owen EC, et al. (2026). Weight loss with a lower dose compounded semaglutide and behavioral weight management program: A real-world matched retrospective cohort study medRxiv preprint. Source
  6. [6] U.S. Food and Drug Administration (2026). FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss FDA. Source
  7. [7] U.S. Food and Drug Administration (2026). FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize FDA. Source

Where to get it

Price the injectable sellers

The desk lists every seller that publishes an injectable figure, with the advertised price struck against the one a buyer is billed.

Open the price desk →

More in Evidence